🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +19.26% on $OC in just 23h 32m.
IMV
$IMVT
🔒 US EquitiesImmunovant Inc
AVG HISTORICAL GAP
+0.07%
MAX GAP RECORD
+15.79%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $IMVT
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$IMVT
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Nov 09, 2026 Earnings Release 2026-11-09 (BEFORE OPEN (07:00)) | 🔮 UPCOMING 🔒 |
| Aug 06, 2026 Earnings Release 2026-08-06 (BEFORE OPEN) |
-3.31%
|
| May 20, 2026 Earnings Release 2026-05-20 (BEFORE OPEN) |
+15.79%
|
| Feb 06, 2026 Earnings Release 2026-02-06 (BEFORE OPEN) |
+11.72%
|
| Nov 10, 2025 Earnings Release 2025-11-10 (BEFORE OPEN) |
-2.53%
|
| Aug 11, 2025 Earnings Release 2025-08-11 (BEFORE OPEN) |
+0.26%
|
| May 28, 2025 Earnings Release 2025-05-28 (BEFORE OPEN) |
+0.07%
|
| Feb 06, 2025 Earnings Release 2025-02-06 (BEFORE OPEN) |
+2.18%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
4.1%
Bullish Gaps (3)
Bearish Gaps (6)
Neutral / Flat (6)
📖 Intelligence Summary
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It develops a novel, fully human monoclonal antibody, IMVT-1401, which selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded on July 6, 2018 and is headquartered in…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗